Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

Sunesis expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

SUNESIS PHARMACEUTICALS, INC.

CONSOLIDATED BALANCE SHEETS

December 31, December 31,

2007 2006

ASSETS (Note 1)

Current assets:

Cash and cash equivalents $11,726,126 $6,075,449

Marketable securities 35,957,933 57,029,199

Prepaids and other current

assets 945,583 1,082,817

Total current assets 48,629,642 64,187,465

Property and equipment, net 4,238,498 4,728,929

Deposits and other assets 377,798 359,974

Total assets $53,245,938 $69,276,368

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable and other

accrued liabilities $4,515,426 $3,439,422

Accrued compensation 2,225,868 2,323,742

Current portion of deferred

revenue 1,227,031 2,260,478

Current portion of equipment

financing 953,940 885,273

Total current liabilities 8,922,265 8,908,915

Non-current portion of deferred

revenue - 1,143,159

Non
'/>"/>

SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... , Sept. 29, 2014 /PRNewswire/ - Portage Biotech Inc. ("Portage" ... is pleased to announce that its three Promissory Note ... who advanced $ 100,000 each in July 2014 for ... Notes and related Coupons converted into 3,500,001 restricted common ... 5% coupon. Both the Note and the coupon were ...
(Date:9/29/2014)... , September 29, 2014 ... research report "Epigenetics Market by Product (Modifying Enzymes, ... Kit, Bisulphite Conversion Kit, Reagents), by Research ... - Global Forecast to 2019", published by ... major drivers, restraints, opportunities, current market trends, ...
(Date:9/29/2014)... YORK , Sept. 29, 2014 ... and The Channel Group ("TCG"), a leader in ... advisors, have formed an alliance to expand the ... prospective clients. With the alliance, Burnham Securities will ... the scientific, clinical medicine and management in healthcare ...
(Date:9/29/2014)... 2014  The 12th Cold Chain GDP & ... September 29 at the John B. Hynes Convention Center. ... for a weeklong conference attracting industry executives ... is designed to cover the industry,s most pressing topics, ... all temperature range products, GDP compliance requirements and supply ...
Breaking Biology Technology:Portage announces conversion of its debt into equity 2Portage announces conversion of its debt into equity 3Epigenetics Market Worth $783.17 Million by 2019 2Epigenetics Market Worth $783.17 Million by 2019 3Epigenetics Market Worth $783.17 Million by 2019 4Burnham Securities Inc. and The Channel Group Form Healthcare Alliance 2Burnham Securities Inc. and The Channel Group Form Healthcare Alliance 312th Cold Chain GDP & Temperature Management Logistics Global Forum Officially Kicks Off in Boston 2
... Therapeutics,Inc. (Nasdaq: IMRX ), a biopharmaceutical company ... financial,results for the first quarter ended March 31, ... Highlights:, -- Entered into agreement with Abbott ... obligation under non-recourse promissory note issued in connection ...
... Spain, May 15 Forest,Laboratories, Inc. (NYSE: ... a webcast to discuss aclidinium bromide clinical and ... Annual Congress.,The webcast, which will include a slide ... May 21, 2008 at 9:30am New York time, ...
... Care Advisory Panel reacts to CMS final rule; ... identifies challenges, recommends ... Industries, Inc. and,the International Expert Wound Care Advisory ... to Improve Pressure,Ulcer Prevention and Treatment: Implications of ...
Cached Biology Technology:ImaRx Therapeutics Reports First Quarter Ended 2008 Financial Results 2ImaRx Therapeutics Reports First Quarter Ended 2008 Financial Results 3ImaRx Therapeutics Reports First Quarter Ended 2008 Financial Results 4ImaRx Therapeutics Reports First Quarter Ended 2008 Financial Results 5ImaRx Therapeutics Reports First Quarter Ended 2008 Financial Results 6ImaRx Therapeutics Reports First Quarter Ended 2008 Financial Results 7Forest Laboratories, Inc. and Laboratorios Almirall, S.A. to Host Webcast to Discuss Aclidinium Bromide Data Presentations at the American Thoracic Society Annual Congress 2International Wound Care Experts, Medline Announce Pressure Ulcer Prevention Consensus Paper 2International Wound Care Experts, Medline Announce Pressure Ulcer Prevention Consensus Paper 3
(Date:9/29/2014)... ago when the supercontinent of Pangea was starting to break ... different kinds of reptiles called phytosaurs and rauisuchids were at ... believed the two top predators didn,t interact much as the ... the land. But those ideas are changing, thanks largely to ... published online in September in the German journal ...
(Date:9/29/2014)... has significant anti-tumour activity in patients with advanced ... disease has progressed after chemotherapy, according to phase ... in Madrid, Spain. , "Reports of lung ... interest because these mutations may be associated with ... lead author Dr David Planchard, pulmonary oncologist at ...
(Date:9/29/2014)... 2014 NXT-ID, Inc. (Nasdaq: NXTD ... authentication company focused on the growing mobile commerce market, ... been named the Company,s Vice-President and Chief Financial Officer ... as Chief Financial Officer. Mr. Pereira will continue to ... a Director. Mr. Miceli, age 56, has ...
Breaking Biology News(10 mins):Tooth buried in bone shows prehistoric predators tangled across land, sea 2Promising results shown with targeted approaches in subsets of non-small cell lung cancer 2Promising results shown with targeted approaches in subsets of non-small cell lung cancer 3NXT-ID, Inc. Names Vice-President and Chief Financial Officer 2NXT-ID, Inc. Names Vice-President and Chief Financial Officer 3
... Chalmers University of Technology have built a very simple ... directions, even though the antenna is smaller than the ... online journal Nature Communications this week ... very low concentrations of gases or biomolecules. A ...
... 2011 The Translational Genomics Research Institute (TGen) is ... $3.5 million grant from Susan G. Komen for the ... form of this cancer that disproportionately affects African-Americans. ... of physicians and scientists called Promise Grants, multi-million dollar, ...
... of Utah researchers have discovered a new class of compounds ... and inhibit it from infecting cells an early step ... virus. Development and laboratory testing of the potential new ... a study set for online publication by Friday in the ...
Cached Biology News:Bimetallic nanoantenna separates colors of light 2TGen breast cancer research benefits from $3.5 million Komen award 2TGen breast cancer research benefits from $3.5 million Komen award 3Targeting HIV's sugar coating 2Targeting HIV's sugar coating 3
Request Info...
Request Info...
... Nebulizers are available in two product models - ... two models is that the 6000AT+ includes a ... drier aerosol for improved detection limits and reduced ... a range of elements by 10-40 times. Note ...
...
Biology Products: